Ascentage Pharma Group Inc.
Nasdaq AAPG · Suzhou , Jiangsu, China
Works in Cardiovascular · Dermatology · ENT · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Ascentage Pharma Group Inc. is a clinical trial sponsor based in Suzhou , Jiangsu, China, listed as Nasdaq AAPG. It has 26 active clinical trials with 5,196 planned participants, across 14 therapeutic areas. Since 2021 it has completed 8 trials and stopped 7 early.
Trial track record · since 2021
Financials · Nasdaq AAPG
Pipeline · 26 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Ascentage Pharma Group Inc
Ascentage Pharma Group Inc is lead sponsor of 26 active clinical trials on ClinicalTrials.gov, with 5,196 planned participants, in Cardiovascular, Dermatology, ENT, GI & liver and other areas. Since 2021 it has completed 8 trials and stopped 7 early.
Ascentage Pharma Group Inc is based in Suzhou , Jiangsu, China and is listed as Nasdaq AAPG. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Ascentage Pharma Group Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
Approve Suite is not affiliated with Ascentage Pharma Group Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.